Core C (Biostatistics &Data Management) provides expert guidance and collaboration in the biostatistical aCore C (Biostatistics &Data Management) provides expert guidance and collaboration in the biostatistical and data management aspects of the design, conduct and analysis of translational research projects generated by the POI. Prior to the initiation of studies. Core staff members consult with POI investigators to help select designs that are efficient and adequately powered. As studies proceed, staff members review data periodically to evaluate adherence to study procedures, data quality, and adequacy of underlying statistical assumptions. When studies are finished, staff members review the data again, produce informative summary tables and graphical displays, conduct correct and efficient statistical analyses, and consult on the design of subsequent studies. Core C data management staff assist Project 1 investigators with the implementation of clinical trials by designing data collection forms, establishing data management systems, managing data, executing data quality control activities, preparing analysis files, producing interim data completeness reports, and archiving data from completed studies. The work of Core C involves close integration with the efforts of all the research projects. Core C staff members have extensive experience supporting cancer research, with strong backgrounds in basic science, translational research, clinical trials, research computing, and data management. With their many years of experience in biomedical research, they stand ready to identify and apply ideal methods for the statistical design and analysis and data management of POI research studies. Core C offers its sen/ices to all P01 projects and cores.

Public Health Relevance

Malignant mesothelioma is currently considered incurable. New approaches are needed. This Core provides the statistical and data management sen/ices to support the clinical and preclinical studies of the Program Project..

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA066726-15A1
Application #
8291484
Study Section
Special Emphasis Panel (ZCA1-RPRB-B (J1))
Project Start
1997-03-01
Project End
2017-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
15
Fiscal Year
2012
Total Cost
$97,246
Indirect Cost
$72,363
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Aggarwal, Charu; Haas, Andrew R; Metzger, Susan et al. (2018) Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion. Mol Ther 26:1198-1205
Moon, Edmund K; Wang, Liang-Chuan S; Bekdache, Kheng et al. (2018) Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines. Oncoimmunology 7:e1395997
Klampatsa, Astero; Haas, Andrew R; Moon, Edmund K et al. (2017) Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM). Cancers (Basel) 9:
Moon, Edmund K; Ranganathan, Raghuveer; Eruslanov, Evgeniy et al. (2016) Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer. Clin Cancer Res 22:436-47
Liu, X; Barrett, D M; Jiang, S et al. (2016) Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice. Blood Cancer J 6:e430
Liu, Xiaojun; Ranganathan, Raghuveer; Jiang, Shuguang et al. (2016) A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. Cancer Res 76:1578-90
O'Hara, Mark; Stashwick, Caitlin; Haas, Andrew R et al. (2016) Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy. Immunotherapy 8:449-60
Sterman, Daniel H; Alley, Evan; Stevenson, James P et al. (2016) Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFN? Combined with Chemotherapy. Clin Cancer Res 22:3791-800
Newick, Kheng; O'Brien, Shaun; Sun, Jing et al. (2016) Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization. Cancer Immunol Res 4:541-51
Andy, Uduak U; Harvie, Heidi S; Smith, Ariana L et al. (2015) Validation of a self-administered instrument to measure adherence to anticholinergic drugs in women with overactive bladder. Neurourol Urodyn 34:424-8

Showing the most recent 10 out of 85 publications